Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...
United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology
United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced...
Sinqi Pharmaceutical Gets NMPA Green Light for SQ-22031 Eye Drops to Treat Dry Eye Syndrome and Neurotrophic Keratitis
Shenyang Sinqi Pharmaceutical Co., Ltd (SHE: 300573), a pharmaceutical company based in China, has received...
Lepu Scientech Secures NMPA Approval for RF Lance, Advancing Atrial Septal Puncture Technology
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading medical technology company based...
Amoy Diagnostics’ APACE Receives Japanese Approval as Companion Diagnostic for MET-Inhibiting Therapies
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a Chinese diagnostics company, has announced that it...
China’s NMPA Gives Tacit Nod to IASO Biotechnology’s IASO-782 for SLE Clinical Trials
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...
Luye Pharma’s Subsidiary Gets NMPA Go-Ahead for First CD228-Targeted ADC BA1302
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a subsidiary of China-based Luye Pharma Group (HKG:...
AbbVie’s Q2 2024 Results Show Resilience Amid Humira Biosimilar Challenges
AbbVie Inc. (NYSE: ABBV) has reported its financial results for the second quarter of 2024,...
Roche’s H1’24 Financials Show 5% Growth, Eye Care and Cancer Therapies Drive Sales
Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO), the Swiss pharmaceutical and diagnostics giant, has reported...
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...
Amoytop Biotech Opts for NASH Drug Candidate KN069 in Licensing Deal with Alphamab Oncology
Xiamen Amoytop Biotech Co., Ltd (SHA: 688278), a biopharmaceutical company based in China, has exercised...
Oneness Biotech and Microbio Partner with CR Double-Crane for Fespixon Commercialization in China
Taiwan’s Oneness Biotech (TPEx.4743) and its partner Microbio (Shanghai) have secured a lucrative licensing deal...
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...
Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China
Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets,...
Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion
Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group...
Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA
Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...
Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal
China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc....
RemeGen Scales Back Private Placement to Fund New Drug R&D
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan,...
China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program
The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...
Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...